Spravato®Verificado en registro oficialModelo de centros designados

Psychiatrische Dienste Aargau (PDAG)

Windisch, Suiza

Tratamiento y acceso

  • Tratamientos ofrecidosesketamine (Spravato)
  • Vía de accesoCubierto por un programa nacional
  • Coste y cobertura (estado en el registro)Reimbursed by mandatory health insurance (OKP/AOS) per SL Limitatio
  • ReembolsoBAG Spezialitätenliste Limitatio: cantonal psychiatric care mandate required; list valid 2025-10-01 to 2028-09-30 Cómo funciona el reembolso en Europa →
  • Teléfono+41 56 462 21 11
  • Sitio webhttps://www.pdag.ch

Sobre este proveedor

Los detalles a continuación están en inglés.

Psychiatrische Dienste Aargau AG (PDAG), the canton of Aargau's public psychiatric institution headquartered at Koenigsfelderstrasse 1 in Windisch, publishes a dedicated esketamine treatment page. The nasal spray for treatment-resistant depression is offered - outpatient and inpatient - by the Interventional Psychiatry unit in building O.11 on the Windisch Koenigsfelden campus, alongside electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS). Patients self-administer the spray under physician supervision and remain monitored for at least two hours; costs are borne by mandatory health insurance when the conditions are met.

Servicios y programas

Los detalles a continuación están en inglés.

  • Esketamine nasal spray treatment for treatment-resistant depression, outpatient and inpatient, for adults 18-64 and 65+
  • Interventional Psychiatry unit (building O.11, Windisch main campus): esketamine, electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS)
  • Self-administration of the spray under physician supervision with at least two hours of medical monitoring after each dose
  • Dosing per PDAG: twice weekly in the first four weeks, then weekly or every two weeks, combined with an oral antidepressant
  • Direct unit contact: +41 56 462 21 53, interventionelle.psychiatrie@pdag.ch (head: Dr. med. Matthias Hilpert)

Preguntas frecuentes

Los detalles a continuación están en inglés.

Who pays for esketamine treatment at PDAG?

PDAG states that, provided the requirements for use of the esketamine spray are fulfilled, costs are covered by mandatory health insurance (OKP). The Swiss Limitatio applies: adults 18-74, at least two adequate antidepressant trials plus one augmentation attempt without sufficient response, CGI-S of 5 or higher, prior insurer approval (Kostengutsprache) and a maximum of 10 months.

What does a treatment session at PDAG look like?

You apply the nasal spray yourself under a physician's supervision at the Interventional Psychiatry unit in Windisch. Because sedation, dissociation or elevated blood pressure can occur, you are medically monitored for at least two hours before discharge. PDAG asks patients not to eat for two hours and not to drink for 30 minutes before the dose.

How often is esketamine given?

According to PDAG, esketamine is administered twice a week during the first four weeks of treatment, then once a week or once every two weeks, always in combination with an oral antidepressant.

¿Considerando alternativas? One of the BAG-designated Spravato centers; see the country guide and the limited-medical-use PAT program.

Verificación

Este registro se tomó directamente de un registro oficial o una lista de programa y se revisa de nuevo con una cadencia continua.

¿Detectó un error? Vea nuestra metodología (en inglés) — allí se explica cómo se comprueban los registros y cómo notificar una corrección.